Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXFORGE vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Treatment of hypertension,Management of hypertension in patients who are not adequately controlled on monotherapy,Initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Hypertension
One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Amlodipine: terminal elimination half-life is 30-50 hours (mean ~35 h), supporting once-daily dosing. Valsartan: terminal half-life is approximately 6 hours, with the combination product dosed once daily due to amlodipine's long half-life.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Amlodipine is extensively metabolized in the liver via CYP3A4 to inactive metabolites. Valsartan is primarily eliminated unchanged in feces and urine; only about 20% is metabolized by CYP2C9.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Valsartan is primarily eliminated via biliary excretion (83%) in feces as unchanged drug; renal excretion accounts for 13% (mostly unchanged). Amlodipine is extensively metabolized in the liver, with 60% of metabolites excreted renally and 20-25% in feces as unchanged drug.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Amlodipine: ~93% bound to plasma proteins. Valsartan: 94-97% bound to serum albumin.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Amlodipine: Vd is approximately 21 L/kg, indicating extensive extravascular distribution. Valsartan: Vd is about 17 L, not weight-adjusted, indicating distribution mainly in plasma and extracellular fluid.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability: Amlodipine 64-90%; Valsartan about 25% (with wide interindividual variability). Food decreases valsartan absorption by about 40-50%, but does not affect amlodipine absorption.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
For GFR 30-60 m L/min: no adjustment. For GFR <30 m L/min: not recommended due to lack of data. Contraindicated if GFR <30 m L/min due to hydrochlorothiazide component.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: not recommended. Child-Pugh C: contraindicated.
Child-Pugh Class B or C: contraindicated; use not recommended.
Safety and efficacy not established in pediatric patients below 18 years.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No dose adjustment required based on age alone. Initiate at lower end of dosing range (5/160 mg) due to potential for increased sensitivity to hypotension. Monitor renal function closely.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Exforge contains valsartan, which can cause fetal harm when used during pregnancy. If pregnancy is detected, discontinue Exforge as soon as possible.
None
Fetal toxicity,Hypotension in salt- or volume-depleted patients,Impaired renal function,Hyperkalemia,Angioedema,Hepatic impairment,Severe obstructive coronary artery disease
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Pregnancy,Hypersensitivity to amlodipine, valsartan, or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid grapefruit juice (increases amlodipine AUC by 56%). High-potassium foods (bananas, oranges, spinach) may increase hyperkalemia risk; no specific restriction but monitor intake if renal impairment.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Pregnancy Category D. First trimester: Potential fetal toxicity; risk of malformations not significantly increased based on limited data. Second and third trimesters: Oligohydramnios, fetal renal dysfunction, skull ossification defects, hypotension, hyperkalemia, and anuria due to angiotensin II receptor antagonist (valsartan) component. Amlodipine may cause fetal hypoxia due to uterine hypoperfusion.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
No data on Exforge in breast milk. Valsartan is excreted in rat milk; amlodipine is excreted in human milk (M/P ratio unknown). Due to potential adverse effects in nursing infants (hypotension, renal effects), avoid breastfeeding. If used, monitor infant for hypotension and renal function.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Exforge is contraindicated in pregnancy. No dose adjustment can mitigate fetal risk. Alternative antihypertensive therapy is recommended. If inadvertently used, discontinue immediately and switch to a safe alternative.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
EXFORGE (amlodipine/valsartan) combines a dihydropyridine calcium channel blocker with an angiotensin II receptor blocker. It is contraindicated in pregnancy (fetal nephrotoxicity, oligohydramnios). Monitor serum potassium and renal function, especially in older adults, volume-depleted patients, or those with renal impairment. Avoid use with aliskiren in patients with diabetes or GFR <60 m L/min. Peripheral edema is less than amlodipine alone due to vasodilation balance.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid grapefruit juice as it increases amlodipine levels and risk of hypotension.,Take the same time each day; do not skip doses or double up.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,Report swelling in hands/feet, irregular heartbeat, or signs of angioedema (swelling of face/lips).
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXFORGE vs ALDORIL D30, answered by our medical review team.
EXFORGE is a Antihypertensive that works by Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXFORGE and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXFORGE is: One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXFORGE and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXFORGE is classified as Category C. Pregnancy Category D. First trimester: Potential fetal toxicity; risk of malformations not significantly increased based on limited data. Second and third trimesters: Oligohydramni. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.